Diffusion-weighted MRI versus 18F-FDG PET/CT: Performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy

American Journal of Roentgenology

Volumn 198, Issue 1, 2012, Pages 75-82

  Ohno, Yoshiharu ^a,b   Koyama, Hisanobu ^a,b   Yoshikawa, Takeshi ^a   Matsumoto, Keiko ^a,c   Aoyama, Nobukazu ^b   Onishi, Yumiko ^a   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Chemoradiotherapy; Diffusion; Lung; MRI; PET; Prediction

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; MITOMYCIN; VINDESINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84455195472     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.6525     Document Type: Article

References (33)

1. World Health Organization. WHO mortality statistics. Geneva, Switzerland: World Health Organization, 1996
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300
3. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123(1 suppl):226S-243S (Pubitemid 36135720)
4. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 1997; 17(suppl 1):S37-S58 (Pubitemid 127673771)
5. Yüksel M, Cermik TF, Karlikaya C, et al. Monitoring the chemotherapeutic response in primary lung cancer using 99mTc-MIBI SPET. Eur J Nucl Med 2001; 28:799-806 (Pubitemid 32662541)
6. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43:39-45
7. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21:2651-2657 (Pubitemid 46606307)
8. 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106
9. Sunaga N, Oriuchi N, Kaira K, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008; 59:203-210 (Pubitemid 351173409)
10. 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med 2010; 51:1344-1348
11. Ohno Y, Adachi S, Kono M, Kusumoto M, Motoyama A, Sugimura K. Predicting the prognosis of non-small cell lung cancer patient treated with conservative therapy using contrast-enhanced MR imaging. Eur Radiol 2000; 10:1770-1781
12. Fujimoto K, Abe T, Müller NL, et al. Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: correlation with tumor vascularity and prognosis. Radiology 2003; 227:786-793 (Pubitemid 36583038)
13. Ohno Y, Nogami M, Higashino T, et al. Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging 2005; 21:775-783 (Pubitemid 40770870)
14. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360:307-308 (Pubitemid 34874724)
15. DeVries AF, Kremser C, Hein PA, et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56:958-965 (Pubitemid 36794026)
16. Mardor Y, Roth Y, Ochershvilli A, et al. Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 2004; 6:136-142 (Pubitemid 38544601)
17. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 2005; 102:5524-5529 (Pubitemid 40530291)
18. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR 2007; 188:1001-1008 (Pubitemid 46496932)
19. Okuma T, Matsuoka T, Yamamoto A, Hamamoto S, Nakamura K, Inoue Y. Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study. Br J Radiol 2009; 82:989-994
20. Kanauchi N, Oizumi H, Honma T, et al. Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg 2009; 35:706-710
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
22. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment - utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 2008; 248:643-654
23. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009; 30:298-308
24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310 (Pubitemid 16134762)
25. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 2007; 188:1622-1635 (Pubitemid 46866868)
26. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007; 34:463-471
27. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, et al. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol 2007; 9:308-317 (Pubitemid 47304781)
28. 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol 2009; 4:816-821
29. Matoba M, Tonami H, Kondou T, et al. Lung carcinoma: diffusion-weighted MR imaging - preliminary evaluation with apparent diffusion coefficient. Radiology 2007; 243:570-577 (Pubitemid 46649714)
30. Mori T, Nomori H, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 2008; 3:358-364 (Pubitemid 351489475)
31. World Health Organization. WHO handbook for reporting the results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979
32. Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 2001; 31:43-56 (Pubitemid 32012602)
33. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122:1037-1057